- Home
- PDS vs XNCR Comparison
PDS vs XNCR Comparison
Compare PDS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDS
- XNCR
- Stock Information
- Founded
- PDS 1951
- XNCR 1997
- Country
- PDS Canada
- XNCR United States
- Employees
- PDS N/A
- XNCR N/A
- Industry
- PDS
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- PDS
- XNCR Health Care
- Exchange
- PDS Nasdaq
- XNCR Nasdaq
- Market Cap
- PDS 629.2M
- XNCR 579.3M
- IPO Year
- PDS N/A
- XNCR 2013
- Fundamental
- Price
- PDS $50.50
- XNCR $8.54
- Analyst Decision
- PDS Buy
- XNCR Buy
- Analyst Count
- PDS 1
- XNCR 7
- Target Price
- PDS $95.00
- XNCR $27.50
- AVG Volume (30 Days)
- PDS 107.4K
- XNCR 855.3K
- Earning Date
- PDS 07-29-2025
- XNCR 08-04-2025
- Dividend Yield
- PDS N/A
- XNCR N/A
- EPS Growth
- PDS N/A
- XNCR N/A
- EPS
- PDS 5.20
- XNCR N/A
- Revenue
- PDS $1,301,611,298.00
- XNCR $127,228,000.00
- Revenue This Year
- PDS $1.35
- XNCR N/A
- Revenue Next Year
- PDS $0.99
- XNCR $28.84
- P/E Ratio
- PDS $9.00
- XNCR N/A
- Revenue Growth
- PDS N/A
- XNCR N/A
- 52 Week Low
- PDS $36.20
- XNCR $7.16
- 52 Week High
- PDS $79.07
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- PDS 65.36
- XNCR 44.94
- Support Level
- PDS $49.65
- XNCR $8.05
- Resistance Level
- PDS $52.07
- XNCR $10.20
- Average True Range (ATR)
- PDS 1.53
- XNCR 0.57
- MACD
- PDS 0.36
- XNCR -0.01
- Stochastic Oscillator
- PDS 81.62
- XNCR 31.40
About PDS Precision Drilling Corporation
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.